A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
Marissa N LevitoJames C CoonsMargaret M VerricoAdrienne SzymkowiakBrianna LeglerEric J DuewekeSandra L Kane-GillPublished in: The Annals of pharmacotherapy (2020)
The Heparin IV DOAC Interference PowerPlan appears to be conducive to positive patient outcomes when evaluating voluntary reported events and may assist clinicians with managing the therapeutic dilemma of this laboratory interference.